[
  {
    "ts": "2025-07-08T12:11:00+00:00",
    "headline": "Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen",
    "summary": "Myrtelle Inc. (\"Myrtelle\" or the \"Company\"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.",
    "url": "https://finance.yahoo.com/news/myrtelle-launches-manufacturing-first-class-121100162.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b89baa80-aee1-3852-b0f2-308ea48b7b0a",
      "content": {
        "id": "b89baa80-aee1-3852-b0f2-308ea48b7b0a",
        "contentType": "STORY",
        "title": "Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen",
        "description": "",
        "summary": "Myrtelle Inc. (\"Myrtelle\" or the \"Company\"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.",
        "pubDate": "2025-07-08T12:11:00Z",
        "displayTime": "2025-07-08T12:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/64fdcaae10fee28b3e23197147e7fbaf",
          "originalWidth": 400,
          "originalHeight": 140,
          "caption": "A clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases. (PRNewsfoto/Myrtelle, Inc)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JIFut_AsKmZVnITYVNiI1Q--~B/aD0xNDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/64fdcaae10fee28b3e23197147e7fbaf.cf.webp",
              "width": 400,
              "height": 140,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HX2cOitgEn0CDGgNzD3iMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/64fdcaae10fee28b3e23197147e7fbaf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/myrtelle-launches-manufacturing-first-class-121100162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/myrtelle-launches-manufacturing-first-class-121100162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]